22 April 2022  
EMA/CHMP/213286/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
NovoSeven 
eptacog alfa (activated) 
On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
NovoSeven. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S. 
The CHMP adopted a new indication for the treatment of severe postpartum haemorrhage. The full 
indications for NovoSeven will therefore be as follows:2 
NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding 
in those undergoing surgery or invasive procedures in the following patient groups: 
• 
• 
• 
• 
• 
in patients with congenital haemophilia with inhibitors to coagulation factors VIII or 
IX > 5 Bethesda Units (BU) 
in patients with congenital haemophilia who are expected to have a high anamnestic 
response to factor VIII or factor IX administration 
in patients with acquired haemophilia 
in patients with congenital FVII deficiency 
in patients with Glanzmann’s thrombasthenia with past or present refractoriness to 
platelet transfusions, or where platelets are not readily available. 
Severe postpartum haemorrhage 
NovoSeven is indicated for the treatment of severe postpartum haemorrhage when 
uterotonics are insufficient to achieve haemostasis. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
